Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Abbott develops low-strength tablet for paediatric HIV patients

Abbott develops low-strength tablet for paediatric HIV patients

13th November 2007

Abbott has developed a low-strength tablet version of its orally-administered HIV treatment Kaletra (lopinavir/ritonavir) for use by paediatric patients.

The tablets do not need to be refrigerated and can be taken with or without a meal. They are smaller in size than original Kaletra tablets and have been approved for use by the US Food and Drug Administration for children over 15 kg in weight.

Designed to complement the existing Kaletra oral solution, the tablets offer increased dosing flexibility, containing 100mg of lopinavir and 25 mg of ritonavir, compared to the 200 mg of lopinavir and 50 mg of ritonavir in the standard tablets.

Abbott reports that it will register the drug and make it available to over two million children with HIV in more than 150 countries worldwide.

Scott Brun, divisional-vice president of infectious diseases and renal development at Abbott, said: “Abbott developed a lower-strength tablet formulation of Kaletra to give physicians an innovative treatment option to help curb the impact of HIV infection in children.”

He added that HIV continues to have a devastating global impact, especially for the children living with the disease.

In July 2007, Reuters reported that the decision by Abbott to reduce the price charged for Kaletra in Brazil had been hailed by the country’s government as an example for the rest of the industry to follow.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.